Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEAMERICAN:CVM NASDAQ:GRML NASDAQ:IZTC NASDAQ:OKUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVMCel-Sci$1.04-26.2%$3.49$0.89▼$13.48$8.83M0.7151,439 shs2.95 million shsGRMLGreenland Mines Ltd. Common Stock$0.47+8.3%$0.51$0.12▼$3.91$56.49M7.613.35 million shs623,068 shsIZTCInvizyne Technologies$9.62-3.8%$9.02$8.50▼$23.00$60.14MN/A37,647 shs4,038 shsOKUROnKure Therapeutics$3.48+1.0%$4.14$1.70▼$5.38$47.49M0.36228,942 shs43,121 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVMCel-Sci-17.06%-38.16%-65.36%-71.86%-80.96%GRMLGreenland Mines Ltd. Common Stock-6.52%-16.60%-17.97%+84.55%+158.88%IZTCInvizyne Technologies0.00%-1.33%-17.78%-7.72%-26.06%OKUROnKure Therapeutics-12.02%-27.27%-20.00%+37.05%+80.10%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVMCel-Sci$1.04-26.2%$3.49$0.89▼$13.48$8.83M0.7151,439 shs2.95 million shsGRMLGreenland Mines Ltd. Common Stock$0.47+8.3%$0.51$0.12▼$3.91$56.49M7.613.35 million shs623,068 shsIZTCInvizyne Technologies$9.62-3.8%$9.02$8.50▼$23.00$60.14MN/A37,647 shs4,038 shsOKUROnKure Therapeutics$3.48+1.0%$4.14$1.70▼$5.38$47.49M0.36228,942 shs43,121 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVMCel-Sci-17.06%-38.16%-65.36%-71.86%-80.96%GRMLGreenland Mines Ltd. Common Stock-6.52%-16.60%-17.97%+84.55%+158.88%IZTCInvizyne Technologies0.00%-1.33%-17.78%-7.72%-26.06%OKUROnKure Therapeutics-12.02%-27.27%-20.00%+37.05%+80.10%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVMCel-Sci 0.00N/AN/AN/AGRMLGreenland Mines Ltd. Common Stock 1.00SellN/AN/AIZTCInvizyne Technologies 0.00N/AN/AN/AOKUROnKure Therapeutics 2.00Hold$27.00676.98% UpsideCurrent Analyst Ratings BreakdownLatest CVM, GRML, OKUR, and IZTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2026OKUROnKure Therapeutics JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/24/2026OKUROnKure Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/22/2026GRMLGreenland Mines Ltd. Common Stock Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/16/2026OKUROnKure Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$34.00 ➝ $27.00(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVMCel-SciN/AN/AN/AN/A$2.32 per shareN/AGRMLGreenland Mines Ltd. Common StockN/AN/AN/AN/A$0.13 per shareN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/AOKUROnKure TherapeuticsN/AN/AN/AN/A$4.11 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVMCel-Sci-$25.41M-$9.77N/AN/AN/AN/A-226.09%-102.18%N/AGRMLGreenland Mines Ltd. Common Stock-$10.55M-$0.32N/AN/AN/AN/A-137.58%-126.00%N/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AN/AOKUROnKure Therapeutics-$59.52M-$4.33N/AN/AN/AN/A-61.02%-55.99%N/ALatest CVM, GRML, OKUR, and IZTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2026Q1 2026OKUROnKure Therapeutics-$0.7425-$1.11-$0.3675-$1.11$0.17 millionN/A3/12/2026Q4 2025OKUROnKure Therapeutics-$1.15-$0.99+$0.16-$0.99N/AN/A2/17/2026Q1 2026CVMCel-SciN/A-$0.68N/A-$0.68N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCVMCel-SciN/AN/AN/AN/AN/AGRMLGreenland Mines Ltd. Common StockN/AN/AN/AN/AN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AOKUROnKure TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVMCel-Sci0.451.391.35GRMLGreenland Mines Ltd. Common StockN/A95.0295.02IZTCInvizyne TechnologiesN/AN/AN/AOKUROnKure TherapeuticsN/A13.7813.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVMCel-Sci12.08%GRMLGreenland Mines Ltd. Common Stock20.07%IZTCInvizyne TechnologiesN/AOKUROnKure Therapeutics90.98%Insider OwnershipCompanyInsider OwnershipCVMCel-Sci14.06%GRMLGreenland Mines Ltd. Common Stock9.90%IZTCInvizyne TechnologiesN/AOKUROnKure Therapeutics17.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVMCel-Sci438.49 million7.30 millionOptionableGRMLGreenland Mines Ltd. Common Stock5121.24 million109.24 millionN/AIZTCInvizyne Technologies296.25 millionN/AN/AOKUROnKure TherapeuticsN/A13.67 million11.23 millionN/ACVM, GRML, OKUR, and IZTC HeadlinesRecent News About These CompaniesOnKure Therapeutics (NASDAQ:OKUR) Cut to "Hold" at JonesTradingMay 10 at 4:51 AM | americanbankingnews.comWall Street Zen Downgrades OnKure Therapeutics (NASDAQ:OKUR) to SellMay 9 at 2:42 AM | americanbankingnews.comOnKure Therapeutics (NASDAQ:OKUR) Downgraded by Wall Street Zen to SellMay 9 at 2:41 AM | marketbeat.comOnKure Therapeutics (OKUR) Receives a Buy from OppenheimerMay 8, 2026 | theglobeandmail.comOnKure Therapeutics (NASDAQ:OKUR) Stock Rating Lowered by JonesTradingMay 8, 2026 | marketbeat.comOnKure Therapeutics war chest nears $200M following spring stock saleMay 6, 2026 | bizwest.comBOnKure Therapeutics (NASDAQ:OKUR) Issues Quarterly Earnings ResultsMay 5, 2026 | marketbeat.comOnKure Therapeutics Reports First Quarter 2026 Financial ResultsMay 5, 2026 | globenewswire.comOnKure Therapeutics (OKUR) Expected to Announce Quarterly Earnings on TuesdayMay 3, 2026 | americanbankingnews.comOnKure Therapeutics (OKUR) Projected to Post Quarterly Earnings on TuesdayApril 28, 2026 | marketbeat.comOnKure Therapeutics (OKUR) price target decreased by 15.13% to 20.60April 28, 2026 | msn.comOnKure Therapeutics (OKUR) Gets a Buy from JonesTradingApril 26, 2026 | theglobeandmail.comShort Interest in OnKure Therapeutics, Inc. (NASDAQ:OKUR) Drops By 57.6%April 26, 2026 | marketbeat.comOnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and ...March 27, 2026 | finance.yahoo.comOnKure to sell $150M in stock to fund drug developmentMarch 27, 2026 | bizwest.comBOnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular AnomaliesMarch 27, 2026 | globenewswire.comOnKure reports nearly $60M cash on hand as drug trials continueMarch 19, 2026 | bizwest.comBOnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 12, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG), OnKure Therapeutics (OKUR) and Praxis Precision Medicines (PRAX)January 24, 2026 | theglobeandmail.comOnKure Therapeutics (OKUR) Price Target Decreased by 10.00% to 27.54November 18, 2025 | msn.comOnKure Therapeutics Announces Sales Agreement with LeerinkNovember 13, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCVM, GRML, OKUR, and IZTC Company DescriptionsCel-Sci NYSEAMERICAN:CVM$1.04 -0.37 (-26.24%) As of 11:04 AM Eastern This is a fair market value price provided by Massive. Learn more.CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.Greenland Mines Ltd. Common Stock NASDAQ:GRML$0.47 +0.04 (+8.35%) As of 10:45 AM EasternGreenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.Invizyne Technologies NASDAQ:IZTC$9.62 -0.38 (-3.80%) As of 05/8/2026Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.OnKure Therapeutics NASDAQ:OKUR$3.48 +0.04 (+1.02%) As of 11:04 AM Eastern This is a fair market value price provided by Massive. Learn more.OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
